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Chemical mixtures and multiple routes of exposure are frequently difficult problems for exposure and risk assessors. Chemicals can interact
synergistically or antagonistically at a variety of physiologic and biochemical loci within target cells. Many of these interactions can be accounted for
with a thorough understanding of the pharmacokinetics of the compounds in the mixture. Many pharmacokinetic processes such as metabolism
and absorption can be impacted by the presence of other chemicals in the environment and diet and as a result of medication. In addition, variations
between responses as a result of different exposure scenarios (route of exposure, frequency, magnitude) can sometimes result from the impacts
upon the pharmacokinetics. Pharmacokinetic models, when properly formulated and tested, can be useful tools to describe and predict the
magnitude of the impact of multichemical and multiroute exposures. Several examples will be used to demonstrate this potentially powerful tool
and how it can impact the risk assessment process.-Environ Health Perspect 102(Suppl 9):133-137 (1994)
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Introduction
Risk management is a complex process per-
formed in part by comparing and contrast-
ing various risks. Risk assessments should be
designed to provide the necessary accurate
information to perform these comparisons
and contrasts. Incomplete risk assessments
effectively become risk management deci-
sions. Such risk management decisions may
not always lead to the best long term policies
for nations and even the world at large.
Incomplete risk assessments can take
many forms. A risk assessment that ignores
key scientific data is an obvious example of
one that could lead to risk-management
decisions that are seriously deficient. Other
more subtle forms of incomplete risk
assessment also exist. Risk assessments that
do not examine the impact ofall the differ-
ent, but realistic, exposure conditions are
woefully inadequate. Those that are not
able to at least examine the potential for
chemical interactions, the reality of most
human exposure scenarios, may be equally
inadequate.
Traditionally, many risk assessments
have been performed using worst case sce-
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narios in both the hazard and exposure
assessments. Conventional wisdom has told
us that such risk assessments protect, by
default, all members of the society. Risk
assessments performed exclusively in this
manner provide the risk manager with no
idea as to the actual number ofpersons at
such worst case levels or who those persons
may be. Can those at greatest risk be iden-
tified? Can suitable protection be provided
for them without necessarily subjecting the
entire population to unnecessary and costly
protection? Would we, for example, not
allow vaccination against a lethal disease
because a very small percentage ofthe pop-
ulation is dangerously sensitive to the vac-
cine? The answer is clearly no. Our
approach is to identify those at unusually
high risk and protect those individuals in
some special manner, while allowing the
rest of the population to be vaccinated.
Given the economic and global pressures
that nations face today, such multitiered
risk assessment methodologies are needed
in the area ofchemical risk assessments.
Risk assessments are generally thought
of as being composed of several compo-
nents including the hazard assessment and
the exposure assessment. Given recent
advances (1,2), risk assessment should also
include the dose assessment as an important
component. Dose assessment would include
estimates of internal doses resulting from
exposure at various conditions. Internal
organ or cell level doses are generally con-
sidered to be more relevant measures of
dose than either exposure or applied dose.
With limited knowledge about the mecha-
nism of action, the exact internal dose
which will serve as the most toxicologically
relevant measure cannot always be known
with absolute certainty. This is a situation
in which several relevant scenarios must be
tried. For example, the mechanism of toxic
action may depend upon either the total
amount ofmetabolic transformation or the
amount ofone specific metabolite interact-
ing with intracellular organelles. In such
cases, the assessor must find ways to esti-
mate both of these putative internal doses
and compare the impacts ofexposure con-
ditions on each. In other cases the complex-
ities are far greater. Different exposure
patterns may or may not impact the relative
amounts of various metabolites being
formed. For example, under a specific expo-
sure pattern greater or lesser ratios ofa toxic
to a nontoxic metabolite may be formed
when compared to a different, yet equally
relevant, exposure pattern. In other cases
toxicity may result from delicate synergism
between parent compound and one or more
metabolites. Differences in exposure pat-
terns can result in measurable differences in
levels ofthese synergistically acting relevant
toxins in the body.
A better understanding ofdoses and the
relevant interaction ofvarious substances
within the body can be gained through the
use ofphysiologically based pharmacoki-
netic (PBPK) and pharmacodynamic
(PBPD) models. This article will illustrate
how PBPK models can be used to help
make more rational decisions when com-
paring risks resulting from different expo-
sure conditions.
Models
Two PBPK models are used in this exer-
cise. They each are structured somewhat
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differently depending upon the exact
modes of toxic action assumed for each
case. The models were developed from a
combination of two other models pub-
lished for specific chemicals. One, pub-
lished in 1990 (3) describes the disposition
ofchloroform in the body. The other, first
presented in 1985 (4) and discussed in
more detail in 1992 (5), describes the dis-
position of2,5-hexanedione within specific
intracellular loci of the brain. The two
models developed for this exercise, while
not at this time intended for any particular
chemical, are actually based on compo-
nents and characteristics ofthe chloroform
and hexanedione models. Like all PBPK
models, these are systems of mass-balance
equations describing the disposition ofthe
parent compound within the body and,
when so desired, its metabolites.
Metabolism is very important in describing
pharmacokinetics because it is often a
major mechanism for clearing chemicals
from the body. It is equally important, and
increasingly more obvious, that metabolites
are also often found to be the toxic species
causing some ofthe clinical and subclinical
adverse endpoints.
The general macroscopic or organ-level
characteristics ofeach model are the same.
The models represent the body as being
composed ofblood, lungs, liver, fat, kid-
ney, and two lumped compartments called
the rapidly and slowly perfused tissues.
These latter two compartments represent
those organs which are not explicitly
defined by separate equations. Equations
are also included to account for complete
mass balance for the parent compound.
The mass-balance equations then also give
the value ofthe total absorbed dose in the
body. Total absorbed dose is often used in
conventional risk assessments. Although
based on the two models cited (3-5), these
models are somewhat uniquely structured.
Both models allow for varied and multi-
route exposure scenarios. Both are capable
ofsimulating continuous, intermittent, and
single exposures by inhalation, zero, and
first-order absorption through the gastroin-
testinal tract. Although intended at the pre-
sent time to track internal disposition of
only one chemical and its metabolites,
modifications can be made to consider
simultaneous exposure to more than one
chemical. As will be discussed, the current
models can account for some aspects of
simultaneous exposure.
Systems of ordinary differential equa-
tions which typically make up PBPK mod-
els are solved using numerical techniques.
A variety of simulation programs can be
written and simulation languages are also
commercially available. Regardless of the
simulation language or program used,
experience has shown that many of these
models are composed ofdifferential equa-
tions under stiffconditions. Thus, the inte-
gration techniques for solving equations at
such stiff conditions are necessary.
Examples ofsuch solution techniques are
Gear's method (6) and the Lawrence
Livermore Solver ofDifferential Equations
(7,8).
Figure 1 shows an overview of both
models. The parent chemical can enter the
body through the lungs and the gastroin-
testinal tract. Clearance is through the
lungs and through metabolism, occurring
in the liver and kidney. Chemical is trans-
ported to each organ through the arterial
blood and what remains in the blood after
extraction by the organ is transported from
the organ by the venous return.
The first model used here, termed
model 1, is based on the assumption that
the particular chemical ofinterest exerts its
toxicity as a result ofa very active metabo-
lite, which upon formation in the liver,
binds immediately with endogenous
hepatic components. It obviously follows
that the toxicity caused as a result of this
binding occurs at the site ofmetabolite for-
mation, in this case the liver. The model is
structured to account for the cumulative
amount of metabolite produced and the
cumulative amount bound to endogenous
components and molecules. It is this
amount ofbound metabolite that is con-
sidered to be toxicologically relevant and of
interest for risk assessment. The parent
compound, its metabolism in other tissues,
and interaction between parent and
metabolites can also, if necessary, be con-
sidered for risk-assessment purposes and
accounted fqr in these models.
The second model, termed model 2,
assumes that slightly different mechanisms
result in toxicity. While the overall macro-
scopic structure is the same, in this model
the metabolite formed can either bind with
endogenous ligands or be cleared from the
liver by other pathways. The bound frac-
tion then incorporates under first-order
kinetic conditions into the endogenous
components such as protein or intranuclear
materials. The concentration ofmetabolite
incorporated is influenced by the forma-
tion process and a concurrent decomposi-
tion process. The decomposition can be the
result of turnover processes within the tis-
sues, such as protein turnover or cellular
death and removal. In this exercise, the
model simulations for the concentration of
Figure 1. Diagrammatic representation of models.
incorporated fraction and the cumulative
area under the curve of incorporated frac-
tion versus time, are tracked and examined
under various exposure conditions. These
have been selected, for illustrative purposes,
to be the toxicologically relevant measures
ofdose.
Scenarios Compared
This illustrative exercise was designed pri-
marily to compare the toxicologically rele-
vant doses produced among different
exposure scenarios. Secondly, comparisons
are between cases in which there are and
are not concomitant exposures to other
chemicals which may modulate certain
metabolic and physiologic processes that in
turn impact the amount of relevant or
effective dose produced in the body.
Five different exposure scenarios are
examined. The ambient mediaexposure con-
centrations for each were adjusted so that
approximately the same absorbed dose
resulted from each scenario. For examination
ofthe effect ofconcomitant exposure, one
exposure scenario was chosen. The impact of
exposure to more than one substance simul-
taneously was examined. For this illustration
the impact upon two physiologically and
biochemically relevant hepatic parameters
was examined. Table 1 shows the scenarios
examined usingeach model.
Table 1. Exposure scenarios used forcomparisons.
Exposure route
Inhalation
Inhalation
Ingestion
Ingestion
Ingestion
Concentration
0.00035 ppm
0.013 ppm
0.0018 mg/l
0.0054mg/l
0.0018 mg/l
Duration or
frequency
6hr
10 min
3 perday,
single
1 perday,
single
1 per day,
repeated
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Results
Figure 2 shows the total mass ofcompound
absorbed after each exposure scenario. As
can be readily observed, the mass absorbed
after the exposure periods are complete is
almost identical for each. The results are
the same whether the simulation was per-
formed using model 1 or model 2.
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Figure 2. Total mass absorbed as estimated by model
1. (a) 6-hr inhalation at 0.00035 ppm; (b) 10-min inhala-
tion at 0.013 ppm; (c) three repeated ingestion doses at
0.0018 mg/I; (d) one ingestion dose at 0.0054 mg/I.
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Figure 3. Arterial blood concentration as estimated by
model 1. (a) 6-hr inhalation at 0.00035 ppm; (b) 10 min
inhalation at0.013 ppm;(c)threerepeated ingestion doses
at0.0018mg/I;(d)oneingestion doseat0.0054mgJl.
Figure 3 shows the results ofthe four
simulation scenarios on the arterial blood
concentration of parent compound.
Obviously, for the arterial blood concentra-
tion as an end point ofinterest, the single
high level inhalation exposure provides the
greatest dose. The lower arterial concentra-
tion after ingestion is due to the first-pass
effect exerted by the liver, and described by
the model. Model results also indicated that
the concentrations in the other organs
closely paralleled that ofthe arterial blood.
Thus it can be concluded that, with regard
to parent compound concentration peaks,
the single high level inhalation scenario gave
the greatest dose. Ifsome acute toxic event is
assumed to occur after the concentration
level reaches a certain threshold, the single
level inhalation exposure has the greatest
potential to induce deleterious effects.
Different and interesting results are
obtained when attention is turned to prod-
ucts of metabolism and interaction of
metabolites with endogenous molecules.
For these cases, the results are scenario and
model dependent. Looking first at the
amount of metabolite bound to intrahep-
atic molecules, Figure 4 shows the results
for model 1. Model 1, it should be remem-
bered, accounts for cumulative amount
bound from the start of the simulated
exposure until the end of the simulation.
Hence, the amount bound reaches a
plateau. Inspection of Figure 4 quickly
reveals that the ingestion routes, because of
the first-pass effect, result in the greatest
amount ofbinding and thus the largest rel-
evant internal dose. Also, note that for the
two inhalation scenarios the cumulative
amounts are nearly equal. The only differ-
ence between these two exposure scenarios
is the time required to reach the peak, with
the peak reached earlier with the higher
concentration exposure.
Figure 5 shows the result for the
amount bound using model 2. This model
is structured to account for clearance ofthe
metabolite from the liver and for the
bound fraction to become further incorpo-
rated into cellular molecules. Thus, the
amounts depicted in Figure 5 are instanta-
neous amounts rather than cumulative
amounts, as were depicted in Figure 4
using Model 1. Again, the ingestion routes
show considerably higher levels ofbound
fractions than the inhalation routes. The
repeated ingestion scenario shows signifi-
cant buildup of the levels with each
repeated exposure. Also, the single higher-
level oral exposure reaches slightly higher
maximum levels than the repeated lower
level-oral exposure.
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Figure 4. Mass of metabolite bound in liver as esti-
mated by model 1. (a) 6-hr inhalation at 0.00035 ppm;
(b) 10-min inhalation at 0.013 ppm; (c) three repeated
ingestion doses at 0.0018 mg/I; (d) one ingestion dose
at 0.0054 mg/I.
Figure 6 shows the results using model
2 for the incorporated concentration. The
ingestion routes again result in higher lev-
els. The exact pattern ofexposure seems to
be less significant than route of exposure.
Note that the incorporated concentration
shows a continuous rise during the expo-
sure, followed by a decline after the expo-
sure has completely ceased, for the case of
repeated ingestion. Although not shown
here, the cumulative area under the curve
ofthe incorporated concentration is higher
for the ingestion routes. Little difference
was observed between each of the two
inhalation scenarios, and also between each
ofthe two ingestion routes.
Next, the impact ofvarying two impor-
tant hepatic parameters was investigated. In
this illustration, both parameters can be
affected by concomitant exposure to more
than one substance. Metabolic induction is
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Figure 5. Concentration of bound metabolite in liver as
estimated by model 2. (a) 6-hr inhalation at 0.00035
ppm; (b) 10-min inhalation at 0.013 ppm;
{c) three repeated ingestion doses at 0.0018 mg/I;
(d) one ingestion dose at0.0054mg/I.
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Figure 6. Concentration of incorporated metabolite in
liver as estimated by model 2. (a) 6-hr inhalation at
0.00035 ppm; (b) 10-min inhalation at 0.013 ppm;
(c) three repeated ingestion doses at 0.0018 mg/I;
(d) one ingestion dose at 0.0054 mg/I.
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Figure 7. Concentration ofincorporated metabolite in liver
as estimated by model 2. (a) Base line levels for binding
capacity and metabolic rate; (b) metabolic rate increased
by1.5-fold; (c)binding capacity increased by1.5-fold.
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Figure 8. Area under the curve of incorporated
metabolite in liver as estimated by model 2. (a) Base
line levels for binding capacity and metabolic rate;
(b) metabolic rate increased by 1.5-fold; (c) binding
capacity increased by 1.5-fold.
known to occur with continued exposure
to many chemicals. Often those induced
enzymes are then more efficient in metabo-
lizing other xenobiotics. Continued expo-
sure may also induce increased numbers of
host sites for binding. This could result
from increased protein synthesis or
increased cellular proliferation. To make
the effects more easily discernible, single
exposure through the ingestion route was
simulated. Figure 7 shows the results for
the incorporated concentration. While
both have an effect it can readily be
observed that increased binding capacity,
for this case, exerts a greater impact on the
peak concentration than does increased
metabolic rate via induction. However as
can be seen by examining Figure 8, the
impact on the integrated incorporated con-
centration is nearly the same for both
inducing the enzyme and for increasing the
binding capacity of endogenous molecules
for the metabolite.
Figures 9 and 10 show the effects of
two-step induction of binding capacity
when there is repeated daily exposure
through ingestion of the compound of
interest. By examining the instantaneous
concentration (Figure 9) one can readily
see at what times the stepwise changes in
induction occurred (i.e., at 72 and 168 hr).
Note that a new pseudo-steady state is
established after each change in the binding
capacity. Figure 10 shows the difference
between the constant binding capacity case
and the induced case. Note that for
repeated exposure, increased binding
capacity has a greater effect over the long
term than it did for the single exposure case
(Figure 8). Clearly, the impact ofincreased
binding is far more significant for cases of
repeated exposure rather than for single-
exposure cases. Also the difference increases
with time and repeated exposure. This lat-
ter point is very significant ifthis is the end
point to be used in risk assessments where
repeated exposure is expected to occur for
long periods during the lifetime.
Conclusions
This exercise is illustrative ofthe power of
PBPK models to compare and contrast the
relevant toxic internal doses that result
from many different exposure scenarios.
The contention here is not that a knowl-
edge ofpharmacokinetics and pharmacoki-
netic models is a panacea that will
eliminate all uncertainties ofthe risk assess-
ment process. It is not even a contention
that these models will identify all of the
uncertainties. Rather, it is contended here
that the processes of model formulation,
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Figure 9. Concentration of incorporated metabolite in
liver as estimated by model 2. (a) Repeated daily
ingestion doses at base line level of binding capacity;
(b) two-step induction of binding capacity.
validation, and implementation are ofgreat
help in making rational risk assessment
decisions. This simple illustration concen-
trated upon pharmacokinetics. Similar
approaches need to be taken with pharma-
codynamic information. Pharmacokinetic
and pharmacodynamic models often
require resource-intensive efforts for their
proper formulation and validation.
However, once formed and validated, they
can greatly reduce the costs of risk and
exposure assessments. As observed in this
illustration, key biologic processes and
exposure scenarios can be readily identified.
Cost-effective experiments, monitoring,
and even amelioration strategies can be
designed and implemented. In this exam-
ple, the exposure route potentially posing
the greater risk is identified.
It should be noted that different toxic
end points often result in different conclu-
sions regarding concern. As discussed in
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Figure 10. Area underthe curve of incorporated metabo-
lite in liver as estimated by model 2. (a) Repeated daily
ingestion doses at base line level of binding capacity;
(b)two-step induction ofbinding capacity.
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the previous section, for this illustration,
when peak concentration of the parent
compound poses the toxic risk, the inhala-
tion route was ofgreater concern. On the
other hand, when some interaction of
metabolite with endogenous substances is
the toxic mechanism, then the ingestion
route poses the greater danger. Similarly,
concurrent exposure to other substances
may impact at many different points in the
physiology and biochemistry ofxenobiotic
processing. Substances which induce
metabolism or those which might increase
the number ofreceptors (e.g., cellular pro-
liferation) clearly impacted the amount of
potentially toxic product formed after
exposure to xenobiotic, as theorized in this
illustration. With adequate knowledge
about mechanisms of action, this type of
exercise can be and has been performed for
avariety ofenvironmental xenobiotics.
Regarding the mechanism, as this illus-
tration has shown, the choice of the end
point greatly influences conclusions. The
choice of dosimeter is crucial for these
more sophisticated risk assessments. Total
absorbed dose has frequently been sug-
gested and used by regulatory agencies as a
dosimeter of choice for many risk assess-
ments. As has been shown here, identical
absorbed masses do not necessarily result in
identical levels of internal and more rele-
vant dosimetrics. Erroneous conclusions
can easily be reached if the inappropriate
dosimetric is chosen. In this case, a number
of different endpoints were chosen. Peak
concentration of parent, amount of
metabolite bound and incorporated were
all examined as the potential significant
toxic measures. The time integral ofincor-
porated concentration was also examined
as one viable risk assessment end point.
The exact significance ofcumulative mea-
sures is not always agreed upon. The his-
tory ofusing cumulative measures in risk
assessments is based on the use of some
measure of total accumulated dose aver-
aged over some time period, often lifetime.
While this may be intuitively attractive for
some pathologic processes, care must be
exercised so as to appropriately apply such
measures. Clearly, the time when dosing or
exposure occurs is also crucial. For exam-
ple, for some chemicals causing fetal toxic-
ity, only doses occurring in specific win-
dows of vulnerability are significant.
Cumulative doses over the entire gestation
period may be irrelevant. The complex and
numerous nonlinearities in pharmacoki-
netic and pharmacodynamic processes and
the time in which they and the exposures
occur need to be carefully taken into
account.
It is well to remember that modeling
and models do not replace well planned
and precisely performed laboratory experi-
ments. Rather, they are adjuncts which
serve to maximize usefulness ofexperimen-
tal results, assist in the more precise plan-
ning ofother meaningful experiments, and
help design cost-effective and meaningful
field monitoring studies. As such, they are
tools to help identify and hopefully reduce
some ofthe many uncertainties inherently
associated with the risk assessment process.
In the end, well-organized assessments
based on experimentation, modeling, and
realistic monitoring and sound scientific
judgment will result in rational and effec-
tive risk management decisions.
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